Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab

DOI: 10.1080/2162402X.2016.1249559

Keywords: Biomarkers, CTLA-4, ipilimumab, melanoma, myeloid-derived suppressor cells

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text